doxorubicin accord 2 mg/ml infuusiokonsentraatti, liuosta varten
accord healthcare b.v. - doxorubicin hydrochloride - infuusiokonsentraatti, liuosta varten - 2 mg/ml - doksorubisiini
doxorubicin medac 2 mg/ml infuusioneste, liuos
medac gesellschaft fÜr klinische spezialprÄparate mbh - doxorubicin hydrochloride - infuusioneste, liuos - 2 mg/ml - doksorubisiini
epirubicin sanoswiss 2 mg/ml injektioneste, liuos
sanoswiss uab - epirubicin hydrochloride - injektioneste, liuos - 2 mg/ml - epirubisiini
epirubicin ebewe 2 mg/ml infuusiokonsentraatti, liuosta varten
ebewe pharma ges.m.b.h. nfg.kg - epirubicin hydrochloride - infuusiokonsentraatti, liuosta varten - 2 mg/ml - epirubisiini
epirubicin medac 2 mg/ml injektioneste, liuos
medac gesellschaft fÜr klinische spezialprÄparate mbh - epirubicin hydrochloride - injektioneste, liuos - 2 mg/ml - epirubisiini
epirubicin accord 2 mg/ml injektio-/infuusioneste, liuos
accord healthcare b.v. - epirubicin hydrochloride - injektio-/infuusioneste, liuos - 2 mg/ml - epirubisiini
idarubicin accord 5 mg / 5 ml injektioneste, liuos
accord healthcare b.v. - idarubicin hydrochloride - injektioneste, liuos - 5 mg / 5 ml - idarubisiini
idarubicin accord 10 mg / 10 ml injektioneste, liuos
accord healthcare b.v. - idarubicin hydrochloride - injektioneste, liuos - 10 mg / 10 ml - idarubisiini
idarubicin accord 20 mg / 20 ml injektioneste, liuos
accord healthcare b.v. - idarubicin hydrochloride - injektioneste, liuos - 20 mg / 20 ml - idarubisiini
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.